Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EPS (Weighted Average and Diluted) (2020 - 2026)

NeuroPace has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.2 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 4.76% year-over-year to -$0.2; the TTM value through Mar 2026 reached -$0.65, up 21.69%, while the annual FY2025 figure was -$0.66, 29.03% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.2 at NeuroPace, down from -$0.08 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.08 in Q4 2025 and troughed at -$0.52 in Q2 2022.
  • A 5-year average of -$0.29 and a median of -$0.26 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 98.56% in 2022 and fell as far as 41.18% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.44 in 2022, then skyrocketed by 50.0% to -$0.22 in 2023, then increased by 22.73% to -$0.17 in 2024, then skyrocketed by 52.94% to -$0.08 in 2025, then plummeted by 150.0% to -$0.2 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NPCE at -$0.2 in Q1 2026, -$0.08 in Q4 2025, and -$0.11 in Q3 2025.